Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gross-Goupil

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Bulletin Du Cancer|April 27, 2010
[Targeted therapies: sequential and combined treatments]M Gross-Goupil, B Escudier
Bulletin Du Cancer|December 10, 1999
[Malignant pleural mesothelioma]M Gross-Goupil, P Ruffié
Bulletin Du Cancer|June 11, 2010
[Bladder cancer and new drugs]C Massard, B Albouy, M Gross-Goupil, et al.
Bulletin Du Cancer|April 27, 2010
[Renal cell carcinoma management and therapies in 2010]B Albouy, M Gross Goupil, B Escudier, et al.
Journal De Radiologie|September 28, 2011
[Rationale for the local treatment of metastases]A Ravaud, S Roca, A Quivy, et al.
Revue Neurologique|May 7, 2019
Asymptomatic stroke is an underestimated side effect of cabozantinibC Bronnimann, I Sibon, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2008
Carcinomas of an unknown primary site: a curable disease?A Levy, C Massard, M Gross-Goupil, et al.
Bulletin Du Cancer|April 27, 2010
[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]A Ravaud, J-C Bernhard, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2009
Incidence of brain metastases in renal cell carcinoma treated with sorafenibC Massard, J Zonierek, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinomaL Albiges, P Barthélémy, M Gross-Goupil, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Bulletin Du Cancer|April 27, 2010
[Targeted therapies: sequential and combined treatments]M Gross-Goupil, B Escudier
Bulletin Du Cancer|December 10, 1999
[Malignant pleural mesothelioma]M Gross-Goupil, P Ruffié
Bulletin Du Cancer|June 11, 2010
[Bladder cancer and new drugs]C Massard, B Albouy, M Gross-Goupil, et al.
Bulletin Du Cancer|April 27, 2010
[Renal cell carcinoma management and therapies in 2010]B Albouy, M Gross Goupil, B Escudier, et al.
Journal De Radiologie|September 28, 2011
[Rationale for the local treatment of metastases]A Ravaud, S Roca, A Quivy, et al.
Revue Neurologique|May 7, 2019
Asymptomatic stroke is an underestimated side effect of cabozantinibC Bronnimann, I Sibon, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2008
Carcinomas of an unknown primary site: a curable disease?A Levy, C Massard, M Gross-Goupil, et al.
Bulletin Du Cancer|April 27, 2010
[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]A Ravaud, J-C Bernhard, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2009
Incidence of brain metastases in renal cell carcinoma treated with sorafenibC Massard, J Zonierek, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinomaL Albiges, P Barthélémy, M Gross-Goupil, et al.
Pageof 4